Stockscreener 앱 받기
148.08
1.39%
-2.09
시간 외 거래:
154.70
6.62
+4.47%
전일 마감가:
$150.17
열려 있는:
$150.09
하루 거래량:
602.61K
Relative Volume:
0.36
시가총액:
$20.07B
수익:
$1.53B
순이익/손실:
$-214.69M
주가수익비율:
-84.14
EPS:
-1.76
순현금흐름:
$-43.68M
1주 성능:
+3.35%
1개월 성능:
-0.78%
6개월 성능:
+21.03%
1년 성능:
+63.93%
1일 변동 폭
$147.13
$150.09
1주일 범위
$141.18
$152.66
52주 변동 폭
$83.13
$183.00
Natera Inc Stock (NTRA) Company Profile
명칭
Natera Inc
전화
650-249-9090
주소
13011 MCCALLEN PASS, AUSTIN, CA
NTRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
148.08 | 20.07B | 1.53B | -214.69M | -43.68M | -1.76 |
|
TMO
Thermo Fisher Scientific Inc
|
427.50 | 169.62B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
186.83 | 138.06B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
411.49 | 32.79B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
102.48 | 29.99B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
143.91 | 26.61B | 15.41B | 1.37B | 2.11B | 7.50 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-08 | 재개 | Craig Hallum | Buy |
| 2024-02-20 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | 재확인 | BTIG Research | Buy |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-11-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | 개시 | Bernstein | Mkt Perform |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-05 | 개시 | UBS | Buy |
| 2023-01-18 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-04-25 | 개시 | Stephens | Overweight |
| 2022-03-08 | 개시 | Goldman | Buy |
| 2022-01-06 | 재개 | Piper Sandler | Overweight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-05-25 | 개시 | Wells Fargo | Overweight |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-10-08 | 개시 | BTIG Research | Buy |
| 2020-09-28 | 개시 | Morgan Stanley | Overweight |
| 2020-09-17 | 개시 | SVB Leerink | Outperform |
| 2020-06-10 | 재개 | Piper Sandler | Overweight |
| 2020-05-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-10-05 | 개시 | JP Morgan | Neutral |
| 2018-07-05 | 재확인 | Piper Jaffray | Overweight |
| 2017-08-07 | 재확인 | Morgan Stanley | Overweight |
| 2016-11-10 | 재확인 | The Benchmark Company | Buy |
| 2016-05-23 | 재확인 | The Benchmark Company | Buy |
| 2016-05-11 | 재확인 | The Benchmark Company | Buy |
| 2016-04-19 | 개시 | The Benchmark Company | Buy |
| 2015-09-28 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2015-08-14 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | 개시 | Robert W. Baird | Outperform |
| 2015-07-27 | 개시 | Morgan Stanley | Equal-Weight |
| 2015-07-27 | 개시 | Piper Jaffray | Overweight |
| 2015-07-27 | 개시 | Wedbush | Neutral |
모두보기
Natera Inc 주식(NTRA)의 최신 뉴스
Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today - Benzinga
The Blood Test Revolution Driving These Three Stocks - Investor's Business Daily
Press Release Distribution & PR Platform - ACCESS Newswire
Lobbying Update: $140,000 of NATERA INC lobbying was just disclosed - Nasdaq
When will cancer return? Personalized Signatera blood test can find early signs of disease - Austin American-Statesman
Natera (NasdaqGS:NTRA) Climbs 11% in One Week - simplywall.st
Barclays Adjusts Natera (NTRA) Price Target Amid Industry Challe - GuruFocus
Assessing Natera: Insights From 10 Financial Analysts - Benzinga
When Will Natera, Inc. (NASDAQ:NTRA) Turn A Profit? - Yahoo Finance
Natera price target lowered to $160 from $200 at Barclays - TipRanks
Natera, Inc. (NTRA): Among Stocks with Buy Ratings that Hedge Funds Love - Insider Monkey
3 Reasons NTRA Has Explosive Upside Potential - Yahoo Finance
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
15 Stocks with Buy Ratings that Hedge Funds Love - Insider Monkey
27.5% of Stanley Druckenmiller's $3.7 Billion Portfolio Is Invested in These 3 Under-the-Radar AI Stocks - Yahoo Finance
Immuno-Oncology Stocks Weather Market Volatility Despite Strong Q4News and Statistics - IndexBox
Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY) - Yahoo Finance
Multi-Cancer Early Detection Market Critical Analysis with Expert Opinion| GRAIL, Natera, Elypta - openPR.com
Insider Selling: Natera, Inc. (NASDAQ:NTRA) CFO Sells 2,562 Shares of Stock - MarketBeat
Natera co-founder Sheena Jonathan sells $826,326 in stock By Investing.com - Investing.com Australia
Natera co-founder Sheena Jonathan sells $826,326 in stock - Investing.com India
Is the Market Bullish or Bearish on Natera? - Benzinga
Natera’s president of clinical diagnostics sells $421,428 in stock By Investing.com - Investing.com South Africa
Natera director Marcus Gail boxer sells $563,100 in stock By Investing.com - Investing.com South Africa
Natera director Marcus Gail boxer sells $563,100 in stock - Investing.com India
Natera’s president of clinical diagnostics sells $421,428 in stock - Investing.com
Natera Inc (NTRA) Shares Up 3.33% on Apr 2 - GuruFocus
Natera CFO Michael Burkes sells $354,603 in stock By Investing.com - Investing.com South Africa
Natera CEO Steven Leonard sells $3.56 million in stock By Investing.com - Investing.com South Africa
Natera’s chief legal officer Daniel Rabinowitz sells $194,326 in stock By Investing.com - Investing.com Australia
Natera CEO Steven Leonard sells $3.56 million in stock - Investing.com Australia
Natera CFO Michael Burkes sells $354,603 in stock - Investing.com
DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 27, 2022 in Natera LawsuitNTRA - Newsfile
Is Natera, Inc. (NASDAQ:NTRA) Trading At A 23% Discount? - simplywall.st
Transforming Colorectal Cancer Management with Tumor-Informed ctDNA Testing - Inside Precision Medicine
Quantbot Technologies LP Makes New $878,000 Investment in Natera, Inc. (NASDAQ:NTRA) - MarketBeat
EFG Asset Management North America Corp. Sells 9,323 Shares of Natera, Inc. (NASDAQ:NTRA) - MarketBeat
Game-Changing Heart Transplant Monitoring Trial Results: 1,100+ Patient Study Could Transform Post-Surgery Care - Stock Titan
Natera’s Busy 2025 Continues - The Healthcare Technology Report.
DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting - Yahoo Finance
(PDF) Understanding the clinical genetics of kidney stone disease using the Natera Renasight panel - ResearchGate
Is Natera, Inc. (NTRA) the Best Diagnostics Stock to Invest in Right Now? - Insider Monkey
Natera Investors Get Class Status in Prenatal Screening Lawsuit - Bloomberg Law News
12 Best Diagnostics Stocks to Invest In Right Now - Insider Monkey
Guardant Health gains amid $292.5M verdict against Natera over false advertising claims (update) - MSN
Natera CFO Michael Burkes sells $115,661 in company stock By Investing.com - Investing.com South Africa
Here’s What Lifted Natera (NTRA) in Q4 and 2024 - MSN
Natera’s president John Fesko sells $116,099 in stock By Investing.com - Investing.com Canada
Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack - Yahoo Finance
Natera’s chief legal officer sells $135,521 in stock By Investing.com - Investing.com Canada
Natera president sells $149,835 in stock By Investing.com - Investing.com Canada
Natera Inc (NTRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Natera Inc 주식 (NTRA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sheena Jonathan | CO-FOUNDER |
Apr 04 '25 |
Sale |
133.14 |
3,070 |
408,751 |
255,249 |
| Marcus Gail Boxer | Director |
Apr 01 '25 |
Option Exercise |
19.74 |
4,000 |
78,967 |
13,704 |
| Marcus Gail Boxer | Director |
Apr 01 '25 |
Sale |
140.78 |
4,000 |
563,100 |
9,704 |
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS |
Apr 01 '25 |
Sale |
140.48 |
3,000 |
421,428 |
141,782 |
| Brophy Michael Burkes | CHIEF FINANCIAL OFFICER |
Mar 31 '25 |
Sale |
138.41 |
2,562 |
354,603 |
75,557 |
| Chapman Steven Leonard | CEO AND PRESIDENT |
Apr 01 '25 |
Sale |
140.48 |
15,898 |
2,233,330 |
196,643 |
| Chapman Steven Leonard | CEO AND PRESIDENT |
Mar 31 '25 |
Sale |
138.41 |
9,563 |
1,323,617 |
212,541 |
| RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL OFFICER |
Mar 31 '25 |
Sale |
138.41 |
1,404 |
194,327 |
225,281 |
0.03%
자본화:
|
볼륨(24시간):